Every material Form 8-K PRECISION BIOSCIENCES INC has filed with the SEC since November 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PRECISION BIOSCIENCES INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →